Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Sharp and Dohme LLC | 1,389 |
| 2 | AbbVie Inc | 1,246 |
| 3 | Procter and Gamble Co | 739 |
| 4 | Purdue Pharma LP | 627 |
| 5 | Genentech Inc | 510 |
| 6 | F Hoffmann La Roche AG | 482 |
| 7 | Takeda Pharmaceutical Co Ltd | 467 |
| 8 | Pfizer Inc | 463 |
| 9 | Amgen Inc | 362 |
| 10 | Abbott Laboratories | 355 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 42,880 |
| 2 | A61K | Medicinal preparations | 40,820 |
| 3 | C07D | Heterocyclic compounds | 19,359 |
| 4 | C07K | Peptides | 9,018 |
| 5 | Y02A | Climate change adaptation | 4,244 |
| 6 | C07C | Acyclic and carbocyclic compounds | 3,600 |
| 7 | C12N | Microorganisms, enzymes | 3,525 |
| 8 | G01N | Investigating / analysing materials | 3,098 |
| 9 | A61L | Sterilising / disinfecting materials | 2,749 |
| 10 | A61Q | Cosmetics, personal care | 2,377 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Drug-Induced Adverse Reactions | 2 |
| 2 | Inflammatory mediators and NSAID effects | 2 |
| 3 | Computational Drug Discovery Methods | 1 |
| 4 | Drug-Induced Hepatotoxicity and Protection | 1 |
| 5 | Musculoskeletal pain and rehabilitation | 1 |
| 6 | Porphyrin Metabolism and Disorders | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Barry R. Walker | University of Pennsylvania | 8 |
| 2 | Francesca Maestrelli | University of Florence | 6 |
| 3 | Hans W. Ruelius | University of Pennsylvania | 6 |
| 4 | James Inglese | National Institutes of Health | 6 |
| 5 | Jerome A. Hubsher | Penn Center for AIDS Research | 5 |
| 6 | Ajit Jadhav | National Center for Advancing Translational Sciences | 4 |
| 7 | Anton Simeonov | National Center for Advancing Translational Sciences | 4 |
| 8 | Daniel Merk | Goethe University Frankfurt | 4 |
| 9 | Frank W. Janssen | Penn Center for AIDS Research | 4 |
| 10 | Matthew D. Hall | National Institutes of Health | 4 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Walix?
Which pharmaceutical companies have the most patents associated with compounds in this chemical space?
What research topics are most frequently associated with published work on this compound?
What are the key patent classification areas for this compound?
Which researchers have published the most work on compounds in this chemical space?